News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,287 Results
Type
Article (43392)
Company Profile (436)
Press Release (672459)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (208763)
Career Advice (2021)
Deals (36009)
Drug Delivery (104)
Drug Development (83678)
Employer Resources (173)
FDA (16435)
Job Trends (15102)
News (352926)
Policy (33087)
Tag
Academia (2645)
Accelerated approval (6)
Adcomms (24)
Allergies (87)
Alliances (50971)
ALS (94)
Alzheimer's disease (1432)
Antibody-drug conjugate (ADC) (139)
Approvals (16425)
Artificial intelligence (270)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11843)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (27)
Breast cancer (287)
Cancer (2324)
Cardiovascular disease (186)
Career advice (1689)
Career pathing (30)
CAR-T (158)
Cell therapy (446)
Cervical cancer (19)
Clinical research (67827)
Collaboration (877)
Company closure (1)
Compensation (541)
Complete response letters (24)
COVID-19 (2648)
CRISPR (45)
C-suite (253)
Cystic fibrosis (105)
Data (2242)
Decentralized trials (2)
Denatured (28)
Depression (51)
Diabetes (275)
Diagnostics (6429)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (108)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (87884)
Editorial (41)
Employer branding (21)
Employer resources (147)
Events (115999)
Executive appointments (743)
FDA (17719)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (785)
Gene editing (113)
Generative AI (20)
Gene therapy (329)
GLP-1 (749)
Government (4505)
Grass and pollen (4)
Guidances (67)
Healthcare (19146)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (130)
Indications (30)
Infectious disease (2793)
Inflammatory bowel disease (144)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (98)
Interviews (311)
IPO (16790)
IRA (43)
Job creations (3702)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (498)
Leadership (18)
Legal (7986)
Liver cancer (76)
Lung cancer (328)
Lymphoma (156)
Machine learning (7)
Management (58)
Manufacturing (314)
MASH (70)
Medical device (13532)
Medtech (13537)
Mergers & acquisitions (19760)
Metabolic disorders (721)
Multiple sclerosis (82)
NASH (19)
Neurodegenerative disease (102)
Neuropsychiatric disorders (33)
Neuroscience (2006)
NextGen: Class of 2025 (6755)
Non-profit (4551)
Now hiring (39)
Obesity (387)
Opinion (223)
Ovarian cancer (77)
Pain (91)
Pancreatic cancer (84)
Parkinson's disease (155)
Partnered (21)
Patents (236)
Patient recruitment (113)
Peanut (47)
People (58691)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21306)
Phase II (29917)
Phase III (22118)
Pipeline (1228)
Policy (148)
Postmarket research (2628)
Preclinical (9194)
Press Release (67)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (404)
Real estate (6015)
Recruiting (66)
Regulatory (22752)
Reports (46)
Research institute (2417)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (77)
Series A (140)
Series B (90)
Service/supplier (11)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (30)
Startups (3762)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (40)
The Weekly (48)
Vaccines (709)
Venture capitalists (43)
Weight loss (255)
Women's health (37)
Worklife (17)
Date
Today (141)
Last 7 days (913)
Last 30 days (2693)
Last 365 days (33706)
2025 (11043)
2024 (36301)
2023 (41016)
2022 (52277)
2021 (56764)
2020 (54922)
2019 (47421)
2018 (35699)
2017 (33027)
2016 (32346)
2015 (38398)
2014 (32186)
2013 (27112)
2012 (29226)
2011 (29930)
2010 (28439)
Location
Africa (741)
Alabama (58)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (39338)
Australia (6555)
California (6274)
Canada (2031)
China (536)
Colorado (273)
Connecticut (288)
Delaware (151)
Europe (86074)
Florida (916)
Georgia (207)
Idaho (57)
Illinois (555)
India (25)
Indiana (312)
Iowa (12)
Japan (164)
Kansas (107)
Kentucky (25)
Louisiana (11)
Maine (62)
Maryland (915)
Massachusetts (4759)
Michigan (222)
Minnesota (398)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1765)
New Mexico (30)
New York (1770)
North Carolina (1036)
North Dakota (8)
Northern California (2715)
Ohio (207)
Oklahoma (14)
Oregon (38)
Pennsylvania (1395)
Puerto Rico (12)
Rhode Island (34)
South America (1113)
South Carolina (23)
South Dakota (1)
Southern California (2344)
Tennessee (101)
Texas (927)
United States (23748)
Utah (183)
Virginia (151)
Washington D.C. (64)
Washington State (575)
West Virginia (3)
Wisconsin (55)
716,287 Results for "eureka therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
Eureka Therapeutics, Inc. today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
March 18, 2024
·
2 min read
Business
Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers
Eureka Therapeutics, Inc. today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).
April 2, 2024
·
3 min read
Anaut Announces Japanese Regulatory Approval of AI-Powered Surgical Visualization Tool, Eureka α
Anaut Inc., a pioneering developer in surgical support software led by CEO Dr. Nao Kobayashi, announced regulatory approval of its groundbreaking medical device, “Eureka α”.
May 2, 2024
·
3 min read
Business
Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
Eureka Therapeutics, Inc. today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS ® T-cell receptor platform.
March 14, 2023
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy
NurExone Biologic Inc. is thrilled to announce that the Company has been awarded a 1M New Israeli Shekels (NIS) (~CAD$350K) grant by the Israel Innovation Authority (“ IIA ”) as part of the Israel-Canada bilateral Eureka program.
October 11, 2023
·
6 min read
Biotech Bay
PercAssist Announces First Patient Treated in EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure
PercAssist, Inc., a medical device company developing innovative technology for a minimally invasive, extravascular platform to provide hemodynamic support for chronic heart failure patients, today announced the successful completion of its first patient in the EUREKA First-in-Human clinical study.
September 28, 2023
·
3 min read
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
Drug Development
Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics, Inc. today announced that the California Institute for Regenerative Medicine (CIRM) awarded the Company a $10.6 million grant to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of pediatric patients with refractory/relapsed liver cancer.
June 6, 2023
·
3 min read
Press Releases
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
April 30, 2025
·
8 min read
1 of 71,629
Next
